- JP-listed companies
- PeptiDream Inc.
- Financials
- Accounts payable
PeptiDream Inc. (4587)
Market cap
¥153.7B
P/E ratio
Peptidream develops new drugs using its proprietary PDPS platform and creates radiopharmaceuticals for diagnosing and treating cancer and other diseases.
| Period End | Accounts payable (Million JPY) | YoY (%) |
|---|---|---|
| Dec 31, 2025 | 4,253 | -20.23% |
| Dec 31, 2024 | 5,332 | +66.44% |
| Dec 31, 2023 | 3,204 | -21.48% |
| Dec 31, 2022 | 4,080 | +360.44% |
| Dec 31, 2021 | 886 | -65.42% |
| Dec 31, 2020 | 2,563 |